India’s leading vaccine innovator Bharat Biotech has announced the establishment of a Contract Research, Development, and Manufacturing Organization (CRDMO) division dedicated to cell and gene therapy, marking a strategic expansion into one of the most advanced frontiers in biomedical science.

The new CRDMO arm will focus on providing end-to-end services in research, process development, analytical testing, and GMP manufacturing for emerging therapies in cellular and genetic medicine. This initiative positions Bharat Biotech among a select group of global players with capabilities spanning vaccines, biologics, and next-generation therapeutics.

According to the company, the CRDMO will cater to both domestic and international biotech firms, startups, and research institutions, fostering innovation through collaboration and enabling faster translation of laboratory breakthroughs into clinical applications.

A spokesperson from Bharat Biotech stated, “With the establishment of this CRDMO, we aim to strengthen India’s biomanufacturing ecosystem and accelerate the development of transformative cell and gene therapies. This represents the next phase of our commitment to innovation-driven healthcare.”

The facility will leverage state-of-the-art technologies, including viral vector platforms, stem cell engineering, and advanced genomic tools, to support the development of personalized and precision medicine solutions.

Experts believe Bharat Biotech’s move will significantly boost India’s standing in the global regenerative medicine landscape, as the demand for cell and gene therapies continues to grow rapidly, addressing previously untreatable diseases such as genetic disorders, cancers, and rare metabolic conditions.

The launch of this CRDMO arm not only strengthens Bharat Biotech’s innovation portfolio but also aligns with India’s broader vision of becoming a global hub for advanced biopharmaceutical manufacturing and research